Dosage;
0.9-1.8g daily in 2-3 divided doses. Children: 35-50mg/kg/day in divided doses.
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Miocamen | Menarini Pharmaceuticals | Phillips Pharmaceuticals Ltd. | 600mg | 12 | Tablet | per tablet | KES 1,638.00 |
| Miocamen | Menarini Pharmaceuticals | Phillips Pharmaceuticals Ltd. | 50mg | 120ml | Suspension | per 5ML | KES 1,638.00 |
| Miocamycin more info | |
|---|---|
| Mode Of Action | binds to 50s sub-unit of the bacterial ribosome and inhibits bacterial protein synthesis by preventing attachment of aminoacyl transfer RNA to its acceptor site on the ribosome. This prevents peptide bond formation by peptidyl transferase. |
| Drug Indication | An alternative for penicillin-allergic patients; intestinal amoebiasis, chlamydial, mycoplasmal infections, URTI, LRTI, skin and soft tissue infections, gonococcal male urethritis and female pelvic infections, long term prophylaxis of rheumatic fever, early syphillis in penicillin allergic patients, tetanus, legionnaires disease. |
| Dosage | 0.9-1.8g daily in 2-3 divided doses. Children: 35-50mg/kg/day in divided doses. |
| Special Information | It shows greater in vitro potency than erythromycin against Legionella pneumophila, Mycoplasma hominis, Ureaplasma urealyticum and erythromycin-resistant staphylococcal and streptococcal species. It however possesses poor overall activity against Haemophilus influenzae and Enterobacteriaceae |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Macrolides |